COMP <GO>
CNMD vs MRK // GROSS PROFIT MARGIN
CONMED Corporation (NYSE) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: CNMD 3
— MRK 9
▲ GROSS PROFIT MARGIN LEADER: MRK
LAST: $45.72 (-0.09%) • MKT CAP: $1.36B
gross-margins
54.60%
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
gross-margins
74.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CNMD VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CNMD | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 54.60% | 74.80% | -20.20 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.80% | 20.70% | -12.90 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 11.4x | 15.3x | -3.90 | CNMD | /valuation <GO> |
| Free Cash Flow Yield | 11.07% | 3.42% | +7.65 | CNMD | /fcf-yield <GO> |
| Operating Margin | 7.50% | 34.30% | -26.80 | MRK | /operating-margins <GO> |
| Net Profit Margin | 3.40% | 28.10% | -24.70 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 5.20% | 1.30% | +3.90 | CNMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.82% | 2.26% | -0.44 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.91 | 5.19 | -3.28 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.1 | 51.7 | -4.60 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.9x | 18.4x | +8.50 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.36B | $361.02B | -$359.66B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CNMD REV | MRK REV | CNMD GROSS % | MRK GROSS % | CNMD FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.37B | $65.01B | 54.6% | 74.8% | $150.9M | $12.36B |
| FY 2024 | $1.31B | $64.17B | 56.1% | 76.3% | $153.9M | $18.10B |
| FY 2023 | $1.24B | $60.12B | — | — | $125.3M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CNMD // BETA —
MRK // BETA 0.92